Hillary Lum
Concepts (456)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Advance Care Planning | 48 | 2026 | 244 | 15.590 |
Why?
| | Patient Portals | 9 | 2026 | 52 | 4.040 |
Why?
| | Dementia | 11 | 2026 | 322 | 3.940 |
Why?
| | Palliative Care | 23 | 2026 | 1032 | 3.570 |
Why?
| | Caregivers | 18 | 2026 | 1079 | 2.930 |
Why?
| | Advance Directives | 10 | 2025 | 89 | 2.360 |
Why?
| | Primary Health Care | 17 | 2026 | 1768 | 2.190 |
Why?
| | Aged | 78 | 2026 | 26251 | 1.970 |
Why?
| | Patient Participation | 6 | 2024 | 454 | 1.930 |
Why?
| | Cognitive Dysfunction | 5 | 2026 | 479 | 1.790 |
Why?
| | Hospice Care | 5 | 2023 | 230 | 1.690 |
Why?
| | Skilled Nursing Facilities | 8 | 2026 | 152 | 1.690 |
Why?
| | Physicians | 9 | 2024 | 954 | 1.650 |
Why?
| | Aged, 80 and over | 35 | 2026 | 8351 | 1.640 |
Why?
| | Suicide, Assisted | 6 | 2024 | 32 | 1.630 |
Why?
| | Terminal Care | 6 | 2023 | 284 | 1.610 |
Why?
| | Communication | 15 | 2024 | 979 | 1.490 |
Why?
| | Physician-Patient Relations | 9 | 2024 | 595 | 1.460 |
Why?
| | Huntington Disease | 2 | 2024 | 60 | 1.450 |
Why?
| | Electronic Health Records | 9 | 2026 | 1208 | 1.430 |
Why?
| | Humans | 142 | 2026 | 145625 | 1.330 |
Why?
| | Parkinson Disease | 4 | 2026 | 614 | 1.260 |
Why?
| | Pandemics | 8 | 2025 | 1700 | 1.260 |
Why?
| | Documentation | 5 | 2024 | 202 | 1.210 |
Why?
| | Qualitative Research | 18 | 2026 | 1720 | 1.180 |
Why?
| | Surveys and Questionnaires | 22 | 2026 | 6050 | 1.140 |
Why?
| | Volunteers | 2 | 2019 | 39 | 1.120 |
Why?
| | Subacute Care | 5 | 2024 | 84 | 1.110 |
Why?
| | Hospices | 2 | 2022 | 95 | 1.070 |
Why?
| | Home Care Services | 6 | 2025 | 290 | 1.060 |
Why?
| | Antibodies, Monoclonal | 9 | 2024 | 1511 | 1.050 |
Why?
| | Social Isolation | 2 | 2025 | 73 | 1.040 |
Why?
| | Male | 72 | 2026 | 73014 | 1.040 |
Why?
| | Authorship | 2 | 2026 | 51 | 1.030 |
Why?
| | Emergency Service, Hospital | 6 | 2026 | 2357 | 1.020 |
Why?
| | Heart Failure | 7 | 2023 | 2323 | 1.020 |
Why?
| | Loneliness | 2 | 2025 | 69 | 1.020 |
Why?
| | Female | 76 | 2026 | 79080 | 1.000 |
Why?
| | Quality Improvement | 6 | 2023 | 1325 | 0.970 |
Why?
| | Accidental Falls | 3 | 2026 | 226 | 0.960 |
Why?
| | Adult Children | 1 | 2025 | 27 | 0.880 |
Why?
| | Middle Aged | 36 | 2026 | 36359 | 0.870 |
Why?
| | Object Attachment | 1 | 2025 | 48 | 0.850 |
Why?
| | Health Knowledge, Attitudes, Practice | 6 | 2025 | 1403 | 0.830 |
Why?
| | Patient Care Team | 5 | 2025 | 700 | 0.810 |
Why?
| | Home Health Aides | 1 | 2023 | 5 | 0.800 |
Why?
| | Medical Marijuana | 3 | 2020 | 119 | 0.780 |
Why?
| | Mass Screening | 4 | 2026 | 1300 | 0.780 |
Why?
| | Ambulatory Care Facilities | 3 | 2026 | 267 | 0.750 |
Why?
| | Life Support Care | 2 | 2020 | 44 | 0.740 |
Why?
| | Feasibility Studies | 5 | 2026 | 1125 | 0.740 |
Why?
| | Group Processes | 2 | 2020 | 62 | 0.730 |
Why?
| | Hospice and Palliative Care Nursing | 2 | 2023 | 115 | 0.730 |
Why?
| | Health Services for the Aged | 2 | 2020 | 73 | 0.730 |
Why?
| | Medicare | 5 | 2024 | 907 | 0.720 |
Why?
| | Geriatric Assessment | 3 | 2026 | 238 | 0.720 |
Why?
| | Parent-Child Relations | 1 | 2025 | 266 | 0.720 |
Why?
| | Nursing Homes | 5 | 2026 | 171 | 0.700 |
Why?
| | Antibodies, Neutralizing | 1 | 2024 | 346 | 0.700 |
Why?
| | Interviews as Topic | 7 | 2026 | 926 | 0.660 |
Why?
| | Housing | 1 | 2022 | 141 | 0.650 |
Why?
| | Living Wills | 1 | 2020 | 9 | 0.650 |
Why?
| | Practice Patterns, Physicians' | 3 | 2019 | 1370 | 0.640 |
Why?
| | Outpatients | 2 | 2024 | 437 | 0.640 |
Why?
| | Music Therapy | 1 | 2020 | 24 | 0.640 |
Why?
| | Patient-Centered Care | 3 | 2021 | 551 | 0.630 |
Why?
| | Music | 1 | 2020 | 43 | 0.620 |
Why?
| | Alzheimer Disease | 2 | 2025 | 640 | 0.610 |
Why?
| | Adaptation, Psychological | 1 | 2025 | 718 | 0.600 |
Why?
| | Inservice Training | 2 | 2017 | 114 | 0.590 |
Why?
| | Neurodegenerative Diseases | 1 | 2021 | 147 | 0.580 |
Why?
| | CD40 Antigens | 4 | 2006 | 67 | 0.570 |
Why?
| | Virtual Reality | 1 | 2020 | 82 | 0.570 |
Why?
| | Sports | 1 | 2021 | 216 | 0.570 |
Why?
| | Resuscitation Orders | 4 | 2024 | 48 | 0.550 |
Why?
| | Internship and Residency | 2 | 2021 | 1269 | 0.550 |
Why?
| | Pharmacists | 1 | 2021 | 260 | 0.550 |
Why?
| | Activities of Daily Living | 1 | 2022 | 438 | 0.550 |
Why?
| | Stakeholder Participation | 1 | 2019 | 90 | 0.540 |
Why?
| | Independent Living | 2 | 2018 | 114 | 0.540 |
Why?
| | Attitude of Health Personnel | 7 | 2024 | 1212 | 0.530 |
Why?
| | Patient Discharge | 6 | 2026 | 991 | 0.530 |
Why?
| | Long-Term Care | 3 | 2024 | 116 | 0.510 |
Why?
| | Betacoronavirus | 1 | 2020 | 288 | 0.510 |
Why?
| | Hospitalization | 5 | 2023 | 2468 | 0.510 |
Why?
| | Health Services Accessibility | 3 | 2026 | 1101 | 0.510 |
Why?
| | Physicians, Primary Care | 1 | 2019 | 209 | 0.500 |
Why?
| | Geriatrics | 3 | 2024 | 96 | 0.480 |
Why?
| | Clinical Protocols | 1 | 2018 | 279 | 0.480 |
Why?
| | United States | 17 | 2026 | 16041 | 0.480 |
Why?
| | Social Media | 1 | 2019 | 158 | 0.480 |
Why?
| | Perception | 2 | 2020 | 372 | 0.480 |
Why?
| | Parents | 1 | 2025 | 1393 | 0.470 |
Why?
| | Pilot Projects | 9 | 2026 | 1878 | 0.460 |
Why?
| | Nurse Practitioners | 1 | 2018 | 141 | 0.460 |
Why?
| | Marijuana Use | 4 | 2020 | 218 | 0.450 |
Why?
| | Patient Education as Topic | 5 | 2019 | 769 | 0.450 |
Why?
| | Policy | 1 | 2016 | 147 | 0.450 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 387 | 0.440 |
Why?
| | Coronavirus Infections | 1 | 2020 | 379 | 0.440 |
Why?
| | Patient Care Planning | 4 | 2026 | 170 | 0.440 |
Why?
| | Cardiotonic Agents | 1 | 2015 | 94 | 0.440 |
Why?
| | Drug Utilization | 1 | 2015 | 170 | 0.420 |
Why?
| | Life Change Events | 1 | 2015 | 144 | 0.410 |
Why?
| | Decision Making | 5 | 2026 | 987 | 0.410 |
Why?
| | Adult | 17 | 2026 | 40821 | 0.400 |
Why?
| | Education, Medical | 1 | 2017 | 273 | 0.390 |
Why?
| | Patient Readmission | 4 | 2021 | 771 | 0.390 |
Why?
| | Physician's Role | 1 | 2015 | 222 | 0.390 |
Why?
| | Quality Assurance, Health Care | 1 | 2015 | 339 | 0.380 |
Why?
| | Nurses | 1 | 2015 | 171 | 0.370 |
Why?
| | Cross-Sectional Studies | 6 | 2024 | 5875 | 0.370 |
Why?
| | Endothelium, Vascular | 6 | 2011 | 952 | 0.340 |
Why?
| | Quality of Life | 4 | 2026 | 3187 | 0.340 |
Why?
| | Canada | 5 | 2023 | 430 | 0.340 |
Why?
| | Culture | 1 | 2012 | 121 | 0.340 |
Why?
| | Melanoma, Experimental | 3 | 2006 | 106 | 0.340 |
Why?
| | Interpersonal Relations | 1 | 2014 | 387 | 0.330 |
Why?
| | Patient Selection | 2 | 2025 | 720 | 0.330 |
Why?
| | Retrospective Studies | 9 | 2026 | 17291 | 0.330 |
Why?
| | Emergency Medical Services | 1 | 2018 | 680 | 0.330 |
Why?
| | Patient Navigation | 2 | 2025 | 126 | 0.320 |
Why?
| | Patients | 1 | 2012 | 183 | 0.320 |
Why?
| | Health Status | 1 | 2016 | 822 | 0.320 |
Why?
| | Health Information Exchange | 2 | 2021 | 23 | 0.310 |
Why?
| | Age Factors | 4 | 2025 | 3321 | 0.310 |
Why?
| | Telemedicine | 4 | 2025 | 956 | 0.300 |
Why?
| | Depression | 3 | 2018 | 1566 | 0.300 |
Why?
| | Brain Neoplasms | 1 | 2019 | 1324 | 0.300 |
Why?
| | Cardiac Surgical Procedures | 2 | 2025 | 608 | 0.290 |
Why?
| | Electronic Mail | 2 | 2019 | 63 | 0.290 |
Why?
| | Colorado | 10 | 2026 | 4588 | 0.280 |
Why?
| | Health Communication | 2 | 2019 | 52 | 0.270 |
Why?
| | Influenza, Human | 1 | 2014 | 634 | 0.270 |
Why?
| | Neoplasms | 4 | 2026 | 2944 | 0.260 |
Why?
| | Referral and Consultation | 5 | 2025 | 878 | 0.260 |
Why?
| | Peer Group | 2 | 2020 | 250 | 0.260 |
Why?
| | Cognition | 2 | 2026 | 1286 | 0.260 |
Why?
| | Organizations, Nonprofit | 1 | 2007 | 17 | 0.250 |
Why?
| | Hospital Mortality | 1 | 2012 | 1037 | 0.250 |
Why?
| | Neuroblastoma | 2 | 2006 | 177 | 0.250 |
Why?
| | Social Work | 3 | 2024 | 84 | 0.240 |
Why?
| | Clinical Decision-Making | 2 | 2022 | 364 | 0.240 |
Why?
| | Emergence Delirium | 1 | 2025 | 7 | 0.230 |
Why?
| | Health Resources | 1 | 2007 | 130 | 0.230 |
Why?
| | Peer Review, Research | 1 | 2026 | 36 | 0.230 |
Why?
| | Smartphone | 1 | 2026 | 103 | 0.220 |
Why?
| | Automobile Driving | 2 | 2019 | 156 | 0.220 |
Why?
| | Grounded Theory | 1 | 2025 | 47 | 0.220 |
Why?
| | Anti-Retroviral Agents | 1 | 2007 | 250 | 0.220 |
Why?
| | Immunization, Passive | 1 | 2005 | 90 | 0.210 |
Why?
| | Immunotherapy | 2 | 2008 | 669 | 0.210 |
Why?
| | Empathy | 2 | 2025 | 184 | 0.210 |
Why?
| | Delirium | 1 | 2025 | 106 | 0.210 |
Why?
| | Multimorbidity | 1 | 2025 | 65 | 0.210 |
Why?
| | Telerehabilitation | 1 | 2025 | 49 | 0.200 |
Why?
| | Antibodies, Bispecific | 1 | 2005 | 70 | 0.200 |
Why?
| | Multicenter Studies as Topic | 1 | 2025 | 413 | 0.200 |
Why?
| | Internet | 2 | 2018 | 656 | 0.200 |
Why?
| | Neurology | 1 | 2025 | 107 | 0.200 |
Why?
| | Oncologists | 1 | 2024 | 47 | 0.200 |
Why?
| | Elder Abuse | 1 | 2024 | 50 | 0.200 |
Why?
| | Cardiovascular Diseases | 1 | 2016 | 2218 | 0.200 |
Why?
| | Periodicals as Topic | 1 | 2026 | 209 | 0.190 |
Why?
| | Self Concept | 1 | 2025 | 257 | 0.190 |
Why?
| | T-Lymphocytes | 4 | 2006 | 2007 | 0.190 |
Why?
| | Anesthesiology | 1 | 2026 | 178 | 0.190 |
Why?
| | Sleep Aids, Pharmaceutical | 1 | 2022 | 4 | 0.190 |
Why?
| | Delphi Technique | 3 | 2026 | 347 | 0.190 |
Why?
| | Healthcare Disparities | 2 | 2021 | 728 | 0.180 |
Why?
| | Language | 1 | 2025 | 313 | 0.180 |
Why?
| | Information Dissemination | 1 | 2024 | 224 | 0.180 |
Why?
| | Randomized Controlled Trials as Topic | 2 | 2026 | 1754 | 0.180 |
Why?
| | Interleukin-2 | 3 | 2009 | 434 | 0.180 |
Why?
| | Thrombin | 3 | 1998 | 174 | 0.170 |
Why?
| | Hearing Loss | 1 | 2024 | 177 | 0.170 |
Why?
| | Video Recording | 2 | 2025 | 218 | 0.170 |
Why?
| | Potentially Inappropriate Medication List | 1 | 2021 | 17 | 0.170 |
Why?
| | Death | 1 | 2022 | 129 | 0.170 |
Why?
| | Macrophages, Peritoneal | 3 | 2006 | 89 | 0.170 |
Why?
| | Nitric Oxide | 1 | 2006 | 883 | 0.170 |
Why?
| | Digital Divide | 1 | 2021 | 3 | 0.170 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2006 | 1223 | 0.170 |
Why?
| | Family | 1 | 2026 | 680 | 0.170 |
Why?
| | Macrophages | 2 | 2006 | 1530 | 0.170 |
Why?
| | Recovery of Function | 1 | 2025 | 721 | 0.160 |
Why?
| | Comorbidity | 2 | 2016 | 1652 | 0.160 |
Why?
| | HIV-1 | 1 | 2007 | 911 | 0.160 |
Why?
| | Personhood | 1 | 2020 | 5 | 0.160 |
Why?
| | Deprescriptions | 1 | 2021 | 38 | 0.160 |
Why?
| | Geriatric Psychiatry | 1 | 2020 | 11 | 0.160 |
Why?
| | Macrophage Activation | 3 | 2006 | 182 | 0.160 |
Why?
| | Program Evaluation | 1 | 2025 | 945 | 0.160 |
Why?
| | Clinical Trials as Topic | 1 | 2025 | 1062 | 0.160 |
Why?
| | Multiple Chronic Conditions | 1 | 2020 | 34 | 0.160 |
Why?
| | Receptors, GABA-A | 1 | 2021 | 138 | 0.150 |
Why?
| | Perioperative Care | 1 | 2022 | 229 | 0.150 |
Why?
| | Neuropsychological Tests | 1 | 2025 | 1136 | 0.150 |
Why?
| | Organization and Administration | 1 | 2019 | 14 | 0.150 |
Why?
| | Health Expenditures | 1 | 2021 | 196 | 0.150 |
Why?
| | Sleep Initiation and Maintenance Disorders | 1 | 2022 | 197 | 0.150 |
Why?
| | Health Plan Implementation | 1 | 2020 | 143 | 0.150 |
Why?
| | Communication Barriers | 2 | 2025 | 129 | 0.150 |
Why?
| | Europe | 1 | 2020 | 420 | 0.140 |
Why?
| | Reimbursement Mechanisms | 1 | 2019 | 78 | 0.140 |
Why?
| | Patient Preference | 2 | 2022 | 224 | 0.140 |
Why?
| | Health Personnel | 1 | 2025 | 750 | 0.140 |
Why?
| | Software Design | 1 | 2018 | 25 | 0.140 |
Why?
| | Alcoholism | 1 | 2026 | 830 | 0.140 |
Why?
| | Veterans | 2 | 2025 | 1647 | 0.140 |
Why?
| | Inpatients | 1 | 2023 | 538 | 0.140 |
Why?
| | Recreation | 1 | 2018 | 27 | 0.140 |
Why?
| | Medical Futility | 1 | 2018 | 32 | 0.140 |
Why?
| | Community-Institutional Relations | 1 | 2019 | 101 | 0.140 |
Why?
| | Developed Countries | 1 | 2018 | 38 | 0.140 |
Why?
| | Vascular Diseases | 1 | 2001 | 251 | 0.140 |
Why?
| | Decision Making, Computer-Assisted | 1 | 2018 | 16 | 0.140 |
Why?
| | Prognosis | 2 | 2018 | 4331 | 0.130 |
Why?
| | Cytotoxicity, Immunologic | 4 | 2006 | 224 | 0.130 |
Why?
| | Ecosystem | 1 | 2022 | 483 | 0.130 |
Why?
| | Capillary Permeability | 1 | 1998 | 132 | 0.130 |
Why?
| | Delivery of Health Care, Integrated | 1 | 2021 | 304 | 0.130 |
Why?
| | Isoenzymes | 1 | 1998 | 294 | 0.130 |
Why?
| | Needs Assessment | 1 | 2020 | 403 | 0.130 |
Why?
| | Prostatic Neoplasms | 1 | 2005 | 972 | 0.130 |
Why?
| | Mentoring | 1 | 2020 | 165 | 0.130 |
Why?
| | Research Personnel | 1 | 2019 | 189 | 0.130 |
Why?
| | Clinical Competence | 1 | 2025 | 1261 | 0.130 |
Why?
| | Reading | 1 | 2018 | 132 | 0.130 |
Why?
| | Protein Kinase C | 1 | 1998 | 250 | 0.120 |
Why?
| | Program Development | 1 | 2019 | 365 | 0.120 |
Why?
| | Quality of Health Care | 1 | 2022 | 692 | 0.120 |
Why?
| | Health Services Research | 1 | 2019 | 389 | 0.120 |
Why?
| | Rural Population | 1 | 2022 | 673 | 0.120 |
Why?
| | Universities | 1 | 2019 | 450 | 0.120 |
Why?
| | Brain Ischemia | 1 | 2020 | 362 | 0.120 |
Why?
| | Longitudinal Studies | 2 | 2016 | 3005 | 0.120 |
Why?
| | Neoplasms, Experimental | 2 | 2008 | 163 | 0.120 |
Why?
| | Community Health Services | 1 | 2018 | 229 | 0.120 |
Why?
| | Academic Medical Centers | 1 | 2019 | 560 | 0.120 |
Why?
| | Hypesthesia | 1 | 2016 | 21 | 0.120 |
Why?
| | Postoperative Complications | 2 | 2025 | 2962 | 0.120 |
Why?
| | Cannabis | 2 | 2020 | 519 | 0.120 |
Why?
| | Housing for the Elderly | 1 | 2015 | 7 | 0.110 |
Why?
| | Disease Management | 2 | 2019 | 649 | 0.110 |
Why?
| | Evidence-Based Medicine | 1 | 2019 | 727 | 0.110 |
Why?
| | Financing, Personal | 1 | 2015 | 26 | 0.110 |
Why?
| | Chest Pain | 1 | 2016 | 100 | 0.110 |
Why?
| | Pain Management | 1 | 2019 | 413 | 0.110 |
Why?
| | Calcium | 2 | 1998 | 1181 | 0.110 |
Why?
| | Professional Role | 1 | 2016 | 171 | 0.110 |
Why?
| | Workflow | 1 | 2016 | 181 | 0.110 |
Why?
| | Prospective Studies | 4 | 2025 | 8087 | 0.110 |
Why?
| | Environment | 1 | 2016 | 295 | 0.110 |
Why?
| | Terminology as Topic | 1 | 2017 | 253 | 0.110 |
Why?
| | Young Adult | 3 | 2021 | 14240 | 0.100 |
Why?
| | Family Practice | 1 | 2018 | 422 | 0.100 |
Why?
| | Oxidative Stress | 1 | 2001 | 1367 | 0.100 |
Why?
| | Curriculum | 1 | 2021 | 1074 | 0.100 |
Why?
| | Firearms | 1 | 2020 | 434 | 0.100 |
Why?
| | Cytokines | 4 | 2006 | 2079 | 0.100 |
Why?
| | Cell Line, Tumor | 6 | 2009 | 3538 | 0.100 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 1 | 2021 | 926 | 0.100 |
Why?
| | Residence Characteristics | 1 | 2016 | 385 | 0.100 |
Why?
| | Motivational Interviewing | 1 | 2015 | 121 | 0.100 |
Why?
| | State Medicine | 1 | 2012 | 23 | 0.090 |
Why?
| | Multivariate Analysis | 1 | 2016 | 1531 | 0.090 |
Why?
| | Signal Transduction | 3 | 2001 | 5234 | 0.090 |
Why?
| | Attitude to Health | 1 | 2015 | 419 | 0.090 |
Why?
| | Patient Acceptance of Health Care | 1 | 2018 | 880 | 0.090 |
Why?
| | Risk Factors | 4 | 2025 | 10840 | 0.090 |
Why?
| | Patient Reported Outcome Measures | 1 | 2016 | 502 | 0.080 |
Why?
| | HIV Infections | 1 | 2007 | 3210 | 0.080 |
Why?
| | Glucuronidase | 1 | 2011 | 27 | 0.080 |
Why?
| | Heparan Sulfate Proteoglycans | 1 | 2011 | 23 | 0.080 |
Why?
| | Stroke | 1 | 2020 | 1283 | 0.080 |
Why?
| | Benzodiazepines | 2 | 2022 | 156 | 0.080 |
Why?
| | Chronic Disease | 1 | 2017 | 1824 | 0.080 |
Why?
| | Severity of Illness Index | 1 | 2018 | 2910 | 0.080 |
Why?
| | Respiratory Mechanics | 1 | 1990 | 74 | 0.080 |
Why?
| | Goals | 2 | 2022 | 187 | 0.070 |
Why?
| | Prevalence | 1 | 2016 | 2852 | 0.070 |
Why?
| | Animals | 14 | 2011 | 38030 | 0.070 |
Why?
| | Mice, SCID | 2 | 2006 | 360 | 0.070 |
Why?
| | Receptors, Thrombin | 2 | 1998 | 13 | 0.070 |
Why?
| | Reactive Oxygen Species | 1 | 2011 | 610 | 0.070 |
Why?
| | Killer Cells, Natural | 3 | 2006 | 481 | 0.070 |
Why?
| | Practice Guidelines as Topic | 1 | 2016 | 1581 | 0.070 |
Why?
| | Recombinant Fusion Proteins | 2 | 2008 | 662 | 0.070 |
Why?
| | Nigeria | 1 | 2007 | 24 | 0.060 |
Why?
| | Pulmonary Alveoli | 1 | 1990 | 385 | 0.060 |
Why?
| | Albumins | 3 | 2005 | 119 | 0.060 |
Why?
| | Atherosclerosis | 1 | 2011 | 410 | 0.060 |
Why?
| | Hyperglycemia | 1 | 2011 | 381 | 0.060 |
Why?
| | Colonic Neoplasms | 1 | 2009 | 257 | 0.060 |
Why?
| | Adolescent | 3 | 2021 | 22451 | 0.060 |
Why?
| | Immunologic Memory | 1 | 2009 | 369 | 0.060 |
Why?
| | Religion | 1 | 2007 | 64 | 0.060 |
Why?
| | Hospitals | 2 | 2022 | 730 | 0.060 |
Why?
| | Treatment Outcome | 2 | 2020 | 11744 | 0.060 |
Why?
| | Mice | 8 | 2009 | 18266 | 0.060 |
Why?
| | Mice, Inbred C57BL | 3 | 2006 | 6021 | 0.060 |
Why?
| | NG-Nitroarginine Methyl Ester | 1 | 2006 | 48 | 0.060 |
Why?
| | Mice, Inbred A | 1 | 2006 | 47 | 0.060 |
Why?
| | Proxy | 1 | 2026 | 37 | 0.060 |
Why?
| | Subcutaneous Tissue | 1 | 2006 | 26 | 0.060 |
Why?
| | Hydroxydopamines | 1 | 2005 | 4 | 0.060 |
Why?
| | Toll-Like Receptor 9 | 1 | 2006 | 37 | 0.060 |
Why?
| | Stress, Psychological | 1 | 2014 | 1169 | 0.060 |
Why?
| | Neoplasm Transplantation | 1 | 2006 | 238 | 0.060 |
Why?
| | Mice, Mutant Strains | 1 | 2006 | 290 | 0.060 |
Why?
| | Social Workers | 1 | 2026 | 55 | 0.060 |
Why?
| | Nitric Oxide Synthase | 1 | 2006 | 233 | 0.060 |
Why?
| | Wearable Electronic Devices | 1 | 2026 | 75 | 0.060 |
Why?
| | Mental Status and Dementia Tests | 1 | 2025 | 28 | 0.060 |
Why?
| | Vaccination | 1 | 2014 | 1444 | 0.060 |
Why?
| | Editorial Policies | 1 | 2026 | 45 | 0.060 |
Why?
| | Risk Assessment | 2 | 2025 | 3678 | 0.060 |
Why?
| | Single-Blind Method | 1 | 2026 | 312 | 0.050 |
Why?
| | Preoperative Period | 1 | 2025 | 150 | 0.050 |
Why?
| | Antigen Presentation | 1 | 2006 | 209 | 0.050 |
Why?
| | Self Report | 2 | 2019 | 869 | 0.050 |
Why?
| | Reproducibility of Results | 2 | 2025 | 3396 | 0.050 |
Why?
| | Publishing | 1 | 2026 | 115 | 0.050 |
Why?
| | Tumor Cells, Cultured | 1 | 2006 | 878 | 0.050 |
Why?
| | CD3 Complex | 1 | 2005 | 112 | 0.050 |
Why?
| | Postoperative Period | 1 | 2025 | 344 | 0.050 |
Why?
| | Conscience | 1 | 2024 | 9 | 0.050 |
Why?
| | Lymphocyte Activation | 2 | 2006 | 1136 | 0.050 |
Why?
| | Cell Membrane Permeability | 2 | 1997 | 88 | 0.050 |
Why?
| | Rats | 3 | 2011 | 5574 | 0.050 |
Why?
| | Blood-Brain Barrier | 1 | 2005 | 167 | 0.050 |
Why?
| | Postural Balance | 1 | 2026 | 241 | 0.050 |
Why?
| | Disclosure | 1 | 2023 | 88 | 0.050 |
Why?
| | Immunoconjugates | 1 | 2005 | 138 | 0.050 |
Why?
| | Terminally Ill | 1 | 2023 | 40 | 0.050 |
Why?
| | Specialization | 1 | 2024 | 136 | 0.050 |
Why?
| | Epidemics | 1 | 2024 | 97 | 0.050 |
Why?
| | Enzyme Inhibitors | 1 | 2006 | 820 | 0.050 |
Why?
| | Preoperative Care | 1 | 2025 | 375 | 0.050 |
Why?
| | Lipopolysaccharides | 1 | 2006 | 861 | 0.050 |
Why?
| | Pregnancy Proteins | 1 | 2002 | 36 | 0.050 |
Why?
| | Morals | 1 | 2023 | 84 | 0.050 |
Why?
| | Cross-Over Studies | 1 | 2025 | 612 | 0.050 |
Why?
| | Adenocarcinoma | 1 | 2009 | 927 | 0.040 |
Why?
| | Patient Care | 1 | 2023 | 120 | 0.040 |
Why?
| | Interferon-gamma | 1 | 2005 | 780 | 0.040 |
Why?
| | Cohort Studies | 1 | 2012 | 6045 | 0.040 |
Why?
| | Asia | 1 | 2021 | 69 | 0.040 |
Why?
| | Pharmaceutical Preparations | 1 | 2022 | 172 | 0.040 |
Why?
| | Artificial Intelligence | 1 | 2025 | 385 | 0.040 |
Why?
| | Permeability | 2 | 2005 | 166 | 0.040 |
Why?
| | Neutrophils | 1 | 2006 | 1132 | 0.040 |
Why?
| | Senior Centers | 1 | 2019 | 1 | 0.040 |
Why?
| | Thrombectomy | 1 | 2020 | 79 | 0.040 |
Why?
| | Cell Line | 2 | 2011 | 2809 | 0.040 |
Why?
| | Ownership | 1 | 2020 | 115 | 0.040 |
Why?
| | Leukocytes | 1 | 2001 | 301 | 0.040 |
Why?
| | Factor Analysis, Statistical | 1 | 2020 | 295 | 0.040 |
Why?
| | Interprofessional Relations | 1 | 2021 | 274 | 0.040 |
Why?
| | Mortality | 1 | 2021 | 375 | 0.040 |
Why?
| | Incidence | 1 | 2025 | 2910 | 0.040 |
Why?
| | Confidentiality | 1 | 2019 | 82 | 0.030 |
Why?
| | Protein Kinase C beta | 1 | 1998 | 21 | 0.030 |
Why?
| | RNA, Antisense | 1 | 1998 | 18 | 0.030 |
Why?
| | Safety | 1 | 2020 | 346 | 0.030 |
Why?
| | Vulnerable Populations | 1 | 2020 | 177 | 0.030 |
Why?
| | Tetradecanoylphorbol Acetate | 1 | 1998 | 128 | 0.030 |
Why?
| | Professional-Patient Relations | 1 | 2019 | 146 | 0.030 |
Why?
| | Minority Health | 1 | 2018 | 18 | 0.030 |
Why?
| | Social Values | 1 | 2018 | 40 | 0.030 |
Why?
| | Time Factors | 4 | 2020 | 7079 | 0.030 |
Why?
| | Informed Consent | 1 | 2019 | 194 | 0.030 |
Why?
| | Feedback | 1 | 1998 | 180 | 0.030 |
Why?
| | Interdisciplinary Research | 1 | 2017 | 25 | 0.030 |
Why?
| | Skin | 2 | 1998 | 701 | 0.030 |
Why?
| | California | 1 | 2018 | 473 | 0.030 |
Why?
| | Internationality | 1 | 2017 | 156 | 0.030 |
Why?
| | Students | 1 | 2021 | 647 | 0.030 |
Why?
| | Socioeconomic Factors | 1 | 2020 | 1323 | 0.030 |
Why?
| | Racism | 1 | 2018 | 147 | 0.030 |
Why?
| | Patient Safety | 1 | 2019 | 351 | 0.030 |
Why?
| | Antibodies | 1 | 1997 | 395 | 0.030 |
Why?
| | Stimulation, Chemical | 1 | 1994 | 52 | 0.030 |
Why?
| | Second Messenger Systems | 1 | 1994 | 31 | 0.030 |
Why?
| | Personal Autonomy | 1 | 2015 | 61 | 0.030 |
Why?
| | Delivery of Health Care | 1 | 2020 | 942 | 0.020 |
Why?
| | Biological Transport | 1 | 1994 | 423 | 0.020 |
Why?
| | Flow Cytometry | 2 | 2008 | 1160 | 0.020 |
Why?
| | Pain | 1 | 2018 | 787 | 0.020 |
Why?
| | Rats, Sprague-Dawley | 2 | 2011 | 2533 | 0.020 |
Why?
| | Spleen | 2 | 2004 | 503 | 0.020 |
Why?
| | Streptozocin | 1 | 2011 | 22 | 0.020 |
Why?
| | Anxiety | 1 | 2018 | 1118 | 0.020 |
Why?
| | Lung Volume Measurements | 1 | 1990 | 44 | 0.020 |
Why?
| | Gerbillinae | 1 | 1990 | 73 | 0.020 |
Why?
| | Diabetes Mellitus, Experimental | 1 | 2011 | 198 | 0.020 |
Why?
| | Pressure | 1 | 1990 | 221 | 0.020 |
Why?
| | Hydrogen Peroxide | 1 | 2011 | 337 | 0.020 |
Why?
| | Peptides, Cyclic | 1 | 1989 | 276 | 0.020 |
Why?
| | Child | 1 | 2007 | 22638 | 0.020 |
Why?
| | Apoptosis | 2 | 2006 | 2436 | 0.020 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2011 | 2018 | 0.020 |
Why?
| | Mice, Inbred BALB C | 1 | 2009 | 1244 | 0.020 |
Why?
| | Combined Modality Therapy | 1 | 2009 | 1269 | 0.010 |
Why?
| | Cell Division | 2 | 2002 | 735 | 0.010 |
Why?
| | Horseradish Peroxidase | 1 | 2005 | 26 | 0.010 |
Why?
| | Integrin beta3 | 1 | 2005 | 14 | 0.010 |
Why?
| | Tyrosine 3-Monooxygenase | 1 | 2005 | 72 | 0.010 |
Why?
| | Glucose | 1 | 2011 | 1051 | 0.010 |
Why?
| | Leukemia L5178 | 1 | 2005 | 1 | 0.010 |
Why?
| | CpG Islands | 1 | 2006 | 175 | 0.010 |
Why?
| | Catheter Ablation | 1 | 2009 | 355 | 0.010 |
Why?
| | Jurkat Cells | 1 | 2005 | 115 | 0.010 |
Why?
| | Substantia Nigra | 1 | 2005 | 64 | 0.010 |
Why?
| | Mice, Inbred C3H | 1 | 2005 | 252 | 0.010 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2008 | 928 | 0.010 |
Why?
| | Cell Count | 1 | 2005 | 315 | 0.010 |
Why?
| | Immunophenotyping | 1 | 2006 | 324 | 0.010 |
Why?
| | Liver Neoplasms, Experimental | 1 | 2004 | 26 | 0.010 |
Why?
| | Coculture Techniques | 1 | 2005 | 244 | 0.010 |
Why?
| | Gangliosides | 1 | 2004 | 23 | 0.010 |
Why?
| | Cytoplasm | 1 | 2005 | 253 | 0.010 |
Why?
| | Functional Laterality | 1 | 2005 | 240 | 0.010 |
Why?
| | Mice, Inbred Strains | 1 | 2004 | 384 | 0.010 |
Why?
| | Ligands | 1 | 2005 | 676 | 0.010 |
Why?
| | Dopamine | 1 | 2005 | 295 | 0.010 |
Why?
| | Megakaryocytes | 1 | 2002 | 34 | 0.010 |
Why?
| | Cells, Cultured | 2 | 2002 | 4112 | 0.010 |
Why?
| | CHO Cells | 1 | 2002 | 167 | 0.010 |
Why?
| | Cricetinae | 1 | 2002 | 295 | 0.010 |
Why?
| | Diabetes Mellitus | 1 | 2011 | 1101 | 0.010 |
Why?
| | Neoplasm Metastasis | 1 | 2004 | 693 | 0.010 |
Why?
| | Immunohistochemistry | 1 | 2005 | 1709 | 0.010 |
Why?
| | Bone Marrow Cells | 1 | 2002 | 326 | 0.010 |
Why?
| | Disease Models, Animal | 1 | 2011 | 4565 | 0.010 |
Why?
| | Recombinant Proteins | 1 | 2002 | 1361 | 0.010 |
Why?
| | Hematopoietic Stem Cells | 1 | 2002 | 432 | 0.010 |
Why?
| | Gestational Age | 1 | 2002 | 989 | 0.010 |
Why?
| | Fetus | 1 | 2002 | 798 | 0.010 |
Why?
| | Mice, Knockout | 1 | 2005 | 3121 | 0.010 |
Why?
| | Metabolic Clearance Rate | 1 | 1997 | 115 | 0.010 |
Why?
| | Antibody Specificity | 1 | 1997 | 181 | 0.010 |
Why?
| | Iodine Radioisotopes | 1 | 1997 | 139 | 0.010 |
Why?
| | Microcirculation | 1 | 1997 | 142 | 0.010 |
Why?
| | Serum Albumin | 1 | 1997 | 147 | 0.010 |
Why?
| | Cell Differentiation | 1 | 2002 | 1979 | 0.010 |
Why?
| | Binding Sites | 1 | 1997 | 1306 | 0.010 |
Why?
| | Peptide Fragments | 1 | 1997 | 693 | 0.010 |
Why?
| | Models, Molecular | 1 | 1997 | 1571 | 0.010 |
Why?
| | Pregnancy | 1 | 2002 | 7217 | 0.000 |
Why?
| | Microscopy, Fluorescence | 1 | 1989 | 403 | 0.000 |
Why?
| | Actins | 1 | 1989 | 422 | 0.000 |
Why?
| | Cattle | 1 | 1989 | 938 | 0.000 |
Why?
| | Cell Survival | 1 | 1989 | 1102 | 0.000 |
Why?
| | Cell Membrane | 1 | 1989 | 701 | 0.000 |
Why?
|
|
Lum's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|